The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.

Abstract

BACKGROUND/AIM:

Primary osteosarcoma of the breast is an exceedingly-rare malignant tumor that shares histological characteristics with osteosarcoma of the bone. Since effective therapies have not yet been established, standard therapy for osteosarcoma of the bone was examined in the present study for efficacy against primary osteosarcoma of the breast in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.

MATERIALS AND METHODS:

The PDOX mouse models were established by surgical implantation of the primary osteosarcoma of the breast specimen into the mammary gland of nude mice. Mice with tumors were randomized into four groups, each n=4: control group; cisplatinum (CDDP)-treatment group; doxorubicin (DOX)-treatment group; and CDDP/DOX-combination-treatment group. Mice were treated for twenty-one days, three weeks after implantation. Tumor size and body weight were measured during three weeks of treatment.

RESULTS:

Significant tumor growth inhibition was observed, compared to the control, in the CDDP-treatment group, the DOX-treatment group, and the combination-treatment-group. Only the combination treatment regressed the tumor.

CONCLUSION:

CDDP and DOX which are standard first-line therapies for osteosarcoma, may be clinically effective against primary osteosarcoma of the breast, and in particular, their combination.

• Authors: Nathaniel F Wu, Jun Yamamoto, Yusuke Aoki, Noriyuki Masaki, Carissa Samonte, Justin Wu, Michael Bouvet, Robert M Hoffman
• Journal: Anticancer research (Anticancer Res) Vol. 41 Issue 10 Pg. 4715-4718 (Oct 2021) ISSN: 1791-7530 [Electronic] Greece
• PMID: 34593419 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Doxorubicin
• Cisplatin

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Cisplatin (therapeutic use)
• Disease Models, Animal
• Doxorubicin (therapeutic use)
• Female
• Humans
• Mice
• Mice, Nude
• Osteosarcoma (drug therapy, pathology)
• Tumor Burden (drug effects)
• Xenograft Model Antitumor Assays